GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to use GoodRx to self-pay for both Ozempic and Wegovy at the $499-per-month price at 70,000 U.S. retail pharmacies.

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 drugs at over 70,000 US pharmacies. GoodRx president and CEO Wendy Barnes joins Market Catalysts host Julie Hyman and Yahoo Finance Senior Reporter Anjalee Khemlani to discuss the company’s push for broader access to branded weight-loss medications.

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.